Where is Viatris Inc. (VTRS) Headed According to the Street?

Viatris Inc. (NASDAQ:VTRS) is one of the best healthcare stocks under $50 to invest in. Viatris Inc. (NASDAQ:VTRS) received a rating update from Piper Sandler on January 28, which adjusted the price target on the stock to $12 from $9 while maintaining a Neutral rating on the shares. The rating update came ahead of the quarterly results, with the firm citing strength for the brand business across a range of geographies, along with the possibility of continued steady contribution in developed markets from new product launches.

In a separate development, Viatris Inc. (NASDAQ:VTRS) announced on January 20 the launch of Inpefa® (sotagliflozin) in the United Arab Emirates (UAE), making it the first country within the Viatris territories to commercialize the treatment. The company plans future launches in several countries over the coming years, which supports its strategy of expanding treatment access in key markets outside of Europe and the United States.

Viatris Inc. (NASDAQ:VTRS) further stated that Inpefa is the first and only dual SGLT1/2 inhibitor that holds approval for the treatment of heart failure, and is approved in the UAE and the United States to lower the risk of hospitalization for heart failure, risk of cardiovascular death, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors.

Viatris Inc. (NASDAQ:VTRS) is a global healthcare company that provides healthcare and pharmaceutical products. The company’s medicines and treatments span various therapeutic areas, including oncology, cardiovascular, dermatology, immunology, eye care, gastroenterology, and women’s healthcare. Its operations are divided into the following segments: Developed Markets, Greater China, JANZ, and Emerging Markets.

While we acknowledge the potential of VTRS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.